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Nonalcoholic fatty liver disease (NAFLD) has become one of the most 
prevalent forms of chronic liver disease with a global prevalence of 
approximately 25% among adults.1 NAFLD is the broad umbrella 
term that encompasses the spectrum of FLD. Histologically, NAFLD 
is categorized into nonalcoholic fatty liver (NAFL) or nonalcoholic 
steatohepatitis (NASH).2-4 To meet diagnostic criteria for NAFL, 
individuals	 must	 have	 ≥5%	 hepatic	 steatosis	 without	 evidence	 of	
hepatocellular injury. Alternatively, NASH is defined by the presence 
≥5%	hepatic	steatosis	with	lobular	inflammation	and	hepatocyte	in-
jury (ballooning) with or without hepatic fibrosis.2 It is estimated 
that approximately 20% of individuals with NAFLD have NASH.1,2,5 
Clinical practice guidelines from both the American and European 
liver societies currently recommend liver biopsy as the gold standard 
for diagnosing and staging NASH.2,6 Enrolment in NASH clinical tri-
als and definition of therapeutic response to novel pharmacologic 
agents for NASH are also largely defined using histologic criteria.7 
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Abstract
Introduction: In the setting of the obesity epidemic, nonalcoholic fatty liver disease 
(NAFLD) has become one of the most prevalent forms of chronic liver disease world-
wide. Approximately 25% of adults globally have NAFLD which includes those with 
NAFL, or simple steatosis, and individuals with nonalcoholic steatohepatitis (NASH) 
where inflammation, hepatocyte injury and potentially hepatic fibrosis are found in 
conjunction with steatosis. Individuals with NASH, particularly those with hepatic 
fibrosis, have higher rates of liver-related and overall mortality, making this distinc-
tion of significant clinical importance. One of the core challenges in current clinical 
practice is identifying this subset of individuals with NASH without the use of liver bi-
opsy, the gold standard for both diagnostics and staging disease severity. Identifying 
noninvasive biomarkers, an accurately measured and reproducible parameter, would 
aide in identifying patients eligible for NASH pharmacotherapy clinical trials and to 
help tailor intensity of monitoring required.
Methods, Results and Conclusions: In this review, we highlight both the currently 
available and novel diagnostic and interventional circulating biomarkers under inves-
tigation for NASH, underscoring their accuracy and limitations relevant to our patient 
population and current clinical practice.
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Inclusion criteria for clinical trials generally include fibrosis stage 
of	 ≥F2	 on	 biopsy.	 Primary	 outcomes	 assessing	 response	 to	 novel	
treatment agents are typically defined using changes in the NAFLD 
Activity Score (NAS) paired with stability or improvement in fibro-
sis.7,8 There are several notable limitations in liver biopsy including 
concerns over sampling error and interrater reliability.9 In addition, 
both patients and clinicians are often hesitant to pursue biopsy due 
to its invasive nature with potential for clinical complications includ-
ing severe bleeding and rarely death.10 As a result, liver biopsy is 
infrequently obtained in clinical practice for diagnosis and staging 
of NASH. In real-world clinical practice, providers often use a com-
bination of noninvasive serum tests, imaging results and endoscopic 
findings to arrive at a personalized diagnosis and risk stratification 
for an individual patient.
The clinical differentiation of NAFL vs NASH is important given 
the distinct natural disease course for these two subsets of NAFLD. 
Individuals with NASH are at risk for developing advanced fibrosis 
and cirrhosis and therefore have higher overall and liver-related mor-
tality.2,11-13 NASH patients have also been noted to have significantly 
higher rates of cardiovascular disease and multiple types of cancer in 
addition to hepatocellular carcinoma (HCC).13,14 Recent studies have 
highlighted the significant clinical implications of fibrosis stage be-
yond the impact of NASH itself. Individuals noted to have even early 
stages of fibrosis were found to have significantly increased risk for 
liver-related morbidity and mortality.15-17 Accordingly, a focus on 
identifying and monitoring fibrosis stage may have more of a clinical 
impact than differentiating NAFL from NASH.
Notably, there are heterogeneous rates of disease progression 
across individuals, making management of NASH challenging.18 
Given that a diagnosis of NASH and fibrosis stage has been clearly 
linked to risk of clinical outcomes and eligibility for and definition of 
response to emerging pharmacotherapy, there is a significant unmet 
need to identify noninvasive diagnostic and interventional circu-
lating biomarkers in NASH. By providing accurate, measurable and 
reproducible markers to diagnose and monitor NASH activity and 
fibrosis stage, noninvasive biomarkers will enable us to evaluate risk 
factors for disease progression and identify patients for pharmaco-
therapy. Interventional biomarkers are of particular interest as these 
parameters can assist in monitoring response to treatment. There 
are multiple significant challenges to identifying accurate diagnostic 
and interventional circulating NASH biomarkers. These challenges 
emerge due to the heterogeneous and nonlinear rates of disease 
progression in NASH and uncertainties in the highest yield param-
eters for monitoring risk of clinical outcomes. In this article, we 
summarize the currently available and novel investigative diagnostic 
and interventional circulating biomarkers in NASH to highlight their 
current potential role in clinical practice and outline possibilities for 
future care (Figure 1).
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2  | A SSESSMENT OF HEPATIC STE ATOSIS
In order to meet diagnostic criteria for NAFLD, an individual must 
have	≥5%	steatosis	on	histology	or	≥5.5%	 intrahepatic	 triglyceride	
content by MRI.2 There are several noninvasive circulating biomark-
ers that have been assessed to evaluate degree of hepatic steatosis 
and are outlined below.
2.1 | Clinical decision aides
There are several clinical decision aides to assess for hepatic steato-
sis that combine laboratory data with clinical features (Table 1). The 
Fatty Liver Index (FLI) includes triglycerides (TG), gamma-glutamyl-
transferase (GGT), body mass index (BMI) and waist circumference 
(WC)	and	uses	ultrasound	(US)	as	the	gold	standard	reference.19 The 
FLI has moderate performance characteristics with an area under 
the	 receiver	 operating	 curve	 (AUROC)	 of	 0.84,	 sensitivity	 (Sn)	 of	
84%	and	specificity	(Sp)	of	64%.	The	Hepatic	Steatosis	Index	(HSI)	
also uses US as the gold standard reference and is comprised of 
aspartate aminotransferase (AST)/alanine aminotransferase (ALT), 
sex, BMI and diabetes mellitus (DM).20	The	HSI	has	an	AUROC	0.81,	
Sn	93%	and	Sp	92%.	The	NAFLD	liver	fat	score	uses	a	more	sensi-
tive reference standard, proton magnetic resonance spectroscopy 
(H-MRS). It is an algorithm that includes fasting serum insulin, AST, 
AST/ALT ratios, DM and presence of metabolic syndrome (MetS).21 
The NAFLD liver fat score had superior accuracy compared to the 
FLI	and	HIS	with	an	AUROC	of	0.86-0.87.	A	decision	aide	that	 in-
corporates more specialized parameters not routinely available in 
clinical practice is the SteatoTest. This uses the six components of 
the FibroTest-ActiTest (total bilirubin, GGT, α-macroglobulin, hap-
toglobin, ALT and apolipoprotein AI), total cholesterol, TG, glucose 
and BMI adjusted for age and sex.22 Its diagnostic accuracy is mod-
erate	with	an	AUROC	of	0.79-0.80.	Lastly,	the	NAFLD	ridge	score	
applies a machine-learning algorithm using laboratory results [ALT, 
high-density lipoprotein cholesterol (HDL-C), TG, haemoglobin A1c 
(HbA1c),	and	white	blood	cell	count	(WBC)]	with	comorbidity	data	
[hypertension	 (HTN)].23 The NAFLD ridge score also uses H-MRS 
as a gold standard and has very good diagnostic accuracy with an 
AUROC	of	0.87	and	a	negative	predictive	value	(NPV)	of	96%.
3  | A SSESSMENT OF 
NECROINFL AMMATION
The complex underlying pathophysiology of hepatocyte injury 
involves multiple pathways including but not limited to inflamma-
tion, apoptosis, lipid and glucose metabolism and oxidative stress.24 
Given this, it has been extremely challenging to identify noninvasive 
biomarkers that accurately capture the degree of necroinflammation 
in NASH. Table 2 outlines the performance characteristics of the 
most relevant diagnostic and interventional circulating biomarkers 
for NASH.
3.1 | Serum circulating biomarkers of hepatic 
inflammation
Serum levels of aminotransferases, most commonly ALT, have been 
frequently applied as routinely available markers of hepatic inflam-
mation in NASH. ALT has consistently been shown to have poor 
diagnostic accuracy for NASH, with a Sn of 64%, Sp of 75% and 
an AUROC of approximately 0.60 to detect NASH on liver biopsy 
in multiple studies.25-27 Researchers are continuously working to 
identify serum biomarkers that more accurately capture hepatic in-
flammation	 in	NASH.	Plasminogen	activator	 inhibitor-1	 (PAI-1)	 is	a	
serine protease inhibitor that regulates the fibrinolytic system that 
has been of interest. It has been investigated among patients with 
biopsy-proven NAFLD and been shown to be associated with un-
derlying NASH.28-31	Among	273	patients	with	obesity,	PAI-1	levels	
TA B L E  1   Noninvasive assessment of hepatic steatosis: Clinical decision aides
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Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC, area under the receiver operating curve; BMI, body mass 
index; DM, diabetes mellitus; GGT, gamma-glutamyltransferase; HbA1c, haemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; H-MRS, 
magnetic resonance spectroscopy; HTN, hypertension; MetS, metabolic syndrome; Sn, sensitivity; Sp, specificity; TG, triglycerides; US, ultrasound; 
WBC,	white	blood	cell	count;	WC,	waist	circumference.
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were correlated with severity of steatosis, lobular inflammation, 
hepatocyte ballooning and fibrosis.28 Similar findings were noted 
among patients enrolled in the NASH Clinical Research Network 
where	PAI-1	was	associated	with	histologic	NASH	(OR	1.2,	95%	CI	
1.08-1.34).29
3.2 | Circulating biomarkers of 
hepatocyte apoptosis
Cytokeratin	18	 (CK-18)	 is	 a	major	 intermediate	 filament	protein	 in	
hepatocytes.	 In	 the	 setting	 of	 hepatocyte	 death,	 CK-18	 has	 been	
shown	to	be	released	at	higher	levels	in	NASH	compared	to	NAFL.	CK-
18,	including	multiple	different	CK-18	fragments,	has	been	studied	
extensively in relationship to NASH.32	In	meta-analyses,	CK18-M30	
levels	had	a	pooled	AUROC	of	0.82	(0.76-0.88)	for	identifying	NASH	
with	a	Sn	66%-78%	and	Sp	of	82%-87%.33,34	Levels	of	CK18-M65	
had	 similar	 accuracy	 with	 an	 AUROC	 of	 0.82.35 Interpretation of 
these studies is complicated by the widely variable optimal cut-off 
used to generate the associated Sn and Sp. Numerous models have 
combined	 CK18	 with	 other	 blood-based	 parameters	 and	 clinical	
features and demonstrated improved prediction of NASH among 
individuals with NAFLD.36	A	model	that	combines	CK18	fragments	
with C-terminal cleavage site of procollagen type III N-terminal 
peptide	(Pro-C3),	acetyl-high	mobility	group	box	1	and	patatin-like	
phospholipase	domain-containing	protein	3	(PNPLA3)	rs738409	had	
the highest reported accuracy to diagnose NASH with an AUROC 
of	0.87,	 Sn	71%	and	Sp	87%,	 though	 these	 results	 have	not	 been	
externally validated.37
3.3 | Adipocytokines
Given that adipocytokines are hypothesized to play a central 
role in the pathogenesis of NAFL and NASH, these markers have 
also been the subject of investigation as potential biomarkers for 
disease severity. Fibroblast growth factor 21 (FGF21) is a hor-
mone-like growth factor involved in several metabolic processes 
including lipid metabolism and insulin sensitivity.38 FGF21 inter-
acts with other relevant adipocytokines including adiponectin and 
leptin.	Prior	studies	have	shown	that	chronic	exposure	to	FGF21	
leads to increased adiponectin levels, which has prompted inves-
tigation of an FGF21 analogue as a potential therapeutic agent for 
NASH.39	 A	meta-analysis	 evaluated	 the	 diagnostic	 value	 of	 CK-
18,	FGF-21	or	a	combination	panel	to	diagnose	NASH	and	noted	
highest	Sn	(92%)	and	Sp	(85%)	in	the	combination	panel	compared	
to	 FGF-21	 along	 (Sn	 62%	 Sp	 78%).40 The associated AUROC of 
this	combination	panel	was	0.94	(95%	CI	0.92-0.96)	to	distinguish	
NASH from NAFL.40 Of note, FGF levels fluctuate throughout the 
day due to regulation by genes that display circadian rhythm. Its 
hepatic expression is also highly responsive to food intake.41 As a 
result, this variation in levels throughout the day and FGF-21 levels 
TA B L E  2   Noninvasive circulating and interventional biomarkers for necroinflammation in NASH














Clinical and Biochemical 
Models
NASHTest45,46 Age, sex, weight, height, TG, cholesterol, a2-
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as they relate to fasting vs fed state require further investigation. 
A panel including several adipocytokines (leptin, ghrelin and adi-
ponectin)	yielded	an	AUROC	of	0.79	to	differentiate	patients	with	
NASH from those with NAFL.42 Lastly, another panel that included 
adiponectin,	resistin	and	cleaved	CK-18	had	good	accuracy	in	the	
test	group	(AUROC	0.91)	though	this	dropped	significantly	in	the	
validation group (0.73) to assess for NASH.43
3.4 | Circulating biomarkers of oxidative stress
Identifying biomarkers of oxidative stress that correlate with NASH 
has proven challenging in part due to difficulty in measuring these 
components	 in	 serum	and	 their	 volatile	nature.	Plasma	 levels	of	9	
and	 13-hydroxyoctadecadienoic	 acid	 and	 9-13-oxo-octadecadien-
oic acid, products of free radical-mediated oxidation of linoleic acid, 
were shown to be elevated among patients with NASH compared to 
those with NAFL.44 Markers of lipid oxidation are of particular in-
terest given their principal role in pathogenesis of NASH. Lipidomic 
studies have applied mass spectroscopy to find associations with 
different biomarkers of lipid oxidation with NASH. The oxNASH 
score is comprised of linoleic acid:13-hydroxyoctadecadienoic acid 
(HODE) ratio with AST, age and BMI.44 The oxNASH score provides 
decent	diagnostic	accuracy	with	AUROC	ranging	from	0.74-0.83,	Sn	
81%	and	Sp	97%.44
3.5 | Clinical and biochemical models
Investigators have aimed to improve predictive accuracy by combin-
ing clinical variables with circulating biomarkers to correlate with 
underlying NASH. In general, this approach has yielded improved 
performance	characteristics	with	AUROCs	ranging	from	0.76-0.80	
as outlined in Table 2. The NASHTest combines 13 variables includ-
ing age, sex, weight, height, TG, cholesterol, total bilirubin, ALT, AST, 
GGT, fasting glucose, α2-macroglobulin, haptoglobin and apolipo-
protein A.45,46 Using this combination of variables, the NASHTest 
yielded	an	AUROC	of	0.79	to	differentiate	NAFL	from	NASH.	The	
HAIR test combines HTN, ALT and insulin resistance to provide a 
score for risk of NASH.47 The reported AUROC for the HAIR test was 
very	good	at	0.90.	A	NASH	Diagnostics	Panel	also	has	a	very	good	
AUROC	at	0.91.35,48	This	panel	consists	of	CK-18-M65,	CK18-M30,	
resistin and adiponectin. Two other models that incorporate clinical 
and laboratory data to differentiate NAFL from NASH are the NAFIC 
Score and the Nice Model, both of which have good predictive ac-
curacy as outlined in Table 2.49-51
4  | A SSESSMENT OF FIBROSIS
Investigation regarding noninvasive assessment of fibrosis stage 
in chronic liver disease has been ongoing for many years and ini-
tially was focused among individuals with chronic hepatitis C. More 
recently, these efforts have shifted to focus specifically on individu-
als with NASH as these tests have varying accuracy across different 
disease states. There are a broad array of approaches using circulat-
ing biomarkers including clinical decision aides that combine clinical 
data with serum biomarkers as well as individual markers of extracel-
lular matrix (ECM) turnover (Table 3). Given that fibrosis stage has 
been strongly associated for risk of clinical outcomes and overall 
mortality in NAFL and NASH, identifying noninvasive methods to 
accurately stage fibrosis is essential.52
4.1 | Clinical decision aides
The NAFLD fibrosis score (NFS) is a clinical decision aide computed 
using platelet count, albumin, AST/ALT and three clinical parameters 
(age, BMI and glucose intolerance).53 The NFS has been demon-
strated to have very good performance characteristics for assessing 
likelihood	for	advanced	fibrosis	or	cirrhosis	(AUROC	0.85,	Sn	90%,	
Sp	60%,	NPV	88%,	PPV	82%),	 though	 it	 is	 less	helpful	 in	discrimi-
nating between lower stages of fibrosis.34,53 The Fibrosis-4 index 
(FIB-4)	and	AST	to	platelet	ratio	index	(APRI)	are	two	other	clinical	
decision aides to assess for underlying fibrosis that are not specific 
to NAFLD.54,55 FIB-4 is calculated based on platelet count, AST, 
ALT	and	age,	whereas	APRI	requires	only	platelets	and	AST.	FIB-4	
is thought to have better accuracy for predicting the presence of 
advanced	fibrosis	in	NAFLD	compared	to	APRI.56 Both the NFS and 
FIB-4 index are currently recommended by the American Association 
for the Study of Liver Diseases (AASLD) as useful noninvasive and 
routinely available clinical decision aides to identify patients who 
may benefit from subspecialty evaluation given risk of advanced fi-
brosis.2 A meta-analysis demonstrated that the NFS and FIB-4 have 
similar accuracy for detecting advanced fibrosis in NAFLD (Sn 72% 
vs	32%,	Sp	70%	vs	96%	 respectively;	AUROC	0.84	 for	both).57 In 
clinical practice, approximately 30% of patients will have scores that 
fall in the indeterminate range for these tests, however, which limits 
their utility in these instances.58 There are also limitations in terms of 
generalizability of the performance characteristics reported in deri-
vation studies to the broader population of patients with NAFLD as 
these scores were constructed primarily among middle-aged partici-
pants who had undergone liver biopsy.59,60
Two additional scores of interest to evaluate degree of fibrosis 
in NAFLD are the BAAT and BARD scores. The BAAT score is com-
prised of ALT, TG, BMI and age. For prediction of F0, the BAAT score 
had	an	AUROC	of	0.86,	0.75	for	F2,	0.92	for	F3	and	0.81	for	F4.61 
The BARD score includes AST/ALT, BMI and DM and generated an 
AUROC	of	0.81	 to	differentiate	patients	with	NAFL	vs	 those	with	
more advanced fibrosis.62 Lastly, there is Fibrometer which con-
sists of fasting glucose, AST, ALT, ferritin, platelets, age and weight. 
Fibrometer had one of the highest AUROCs to detect significant fi-
brosis	at	0.94.63 Overall, these noninvasive scoring systems to assess 
degree	of	fibrosis	are	most	useful	for	their	NPV,	but	do	have	notable	
limitations	in	terms	of	their	PPV	and	thus	must	be	applied	correctly	
to patient care in clinical practice.
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4.2 | Serum biomarkers of extracellular 
matrix turnover
There are several panels that incorporate biomarkers of ECM turno-
ver that have been generated to assess correlation with stage of fi-
brosis in NAFLD. The Enhanced Liver Fibrosis (ELF) panel contains 
three matrix turnover proteins [hyaluronic acid (HA), tissue inhibi-
tor	of	metalloproteinase	1	(TIMP-1)	and	N-terminal	procollagen	III-
peptide	(PIIINP)].	In	clinical	studies,	the	ELF	panel	has	been	shown	
to	 have	 excellent	 Sn	 and	 Sp	 (80%	 and	 90%,	 respectively)	with	 an	
AUROC	of	0.90	when	used	to	predict	advanced	fibrosis	or	cirrho-
sis.64,65 The FibroTest incorporates bilirubin, GGT, haptoglobin, 
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α2-macroglobulin and apolipoprotein A. In clinical studies, FibroTest 
was also shown to have good performance characteristics to de-
tect	 advanced	 fibrosis	 in	 NAFLD	 with	 an	 AUROC	 of	 0.88.66 The 
Hepascore incorporates clinical variables in addition to laboratory 
variables (bilirubin, GGT, HA, a2 macroglobulin, age and sex) to as-
sess for significant fibrosis. Among patients with NAFLD, using a cut-
off	of	0.37	yielded	an	AUROC	of	0.81	for	the	Hepascore	to	detect	
advanced fibrosis.67 FIBROSpect is another combination panel that 
is also marketed to assess hepatic fibrosis. FIBROSpect consists of 
α2-microglobulin,	HA	and	TIMP-1.	Among	a	cohort	of	patients	with	
biopsy-proven NAFLD, FIBROSpect detected advanced fibrosis with 
an	AUROC	of	0.87.68	When	combined	with	other	routinely	available	
clinical	 data	 (platelets,	 age,	BMI,	DM),	 a	Pro-C3	based	model	was	
accurate in identifying patients with NAFLD and advanced fibrosis 
with	an	AUROC	of	0.87,	NPV	88%	and	PPV	84%.69 Another model 
constructed	using	ECM	components	of	HA,	CK18	and	TIMP-1	had	
excellent performance to predict advanced fibrosis in NAFLD with 
an	AUROC	of	0.90,	Sn	88%	and	Sp	84%.70
Components of the ECM have also been evaluated in isolation 
as biomarkers to assess fibrosis stage in NASH. A study evaluating 
PIIINP	using	cut-offs	of	6.6	ng/mL	and	11	ng/mL	yielded	a	NPV	of	
95%	and	PPV	of	100%	 for	detecting	 advanced	 fibrosis.71 Another 
marker	of	collagen	synthesis,	Pro-C3,	has	been	investigated	in	iso-
lation among patients with NAFLD to detect advanced fibrosis and 
demonstrated	a	high	AUROC	(0.91)	with	an	NPV	of	97%	and	PPV	of	
56% .72	A	study	evaluating	the	predictive	capability	of	TIMP-1	alone	
to distinguish individuals with NASH from age-matched controls 
yielded	an	excellent	AUROC	of	0.97.73	TIMP-1	has	had	conflicting	re-
sults for fibrosis staging in NAFLD however.74 A recent study noted 
moderate performance for diagnosing significant fibrosis (AUROC 
0.74).75
5  | E VOLVING ARE A S OF INTEREST FOR 
NOVEL BIOMARKERS
5.1 | Genomics
Accumulating evidence highlights the important interaction be-
tween environmental and genetic factors in NAFLD, as reviewed in 
detail in a recent article by Sookoian et al.76 MicroRNAs (miRNAs) are 
short noncoding RNAs that post-transcriptionally regulate gene ex-
pression. Their role as biomarkers in NASH is evolving, though pre-
sent data are insufficient to strongly support their use. miR-122 and 
miR-34a have been correlated with disease severity in NASH.77,78 
Cell-free DNA (cfDNA) has also been evaluated to assess disease 
severity in NASH, particularly as it relates to degree of fibrosis.79 




gene	 (PNPLA3)]	 has	 been	 identified	 as	 a	 consistent	 genetic	modi-
fier in NAFLD.80	PNPLA3	I148M	variant	has	been	shown	to	promote	
hepatic steatosis and stellate cell activation which in turn leads to 
inflammation and fibrogenesis.81,82It has been investigated as a po-
tentially useful biomarker to identify individuals who are more likely 
to respond to lifestyle interventions or bariatric surgery.83,84 The 
rs58542926	polymorphism	in	TM6SF2	has	been	associated	with	re-
duced hepatic capacity to secrete very low-density lipoprotein and 
thus has been associated with hepatic steatosis and steatohepati-
tis.	 Individuals	with	the	TM6SF2	E167K	variant	are	more	suscepti-
ble to NASH and appear to have protection against cardiovascular 
disease.85,86	 The	 relationship	 between	TM6SF2	 rs58542926	poly-
morphism and risk of NAFLD-related fibrosis is unclear, with stud-
ies	 having	 conflicting	 results.	 The	 rs780094	 polymorphism	 at	 the	
glucokinase	regulatory	gene	(GCKR)	locus	is	also	associated	with	an	
increased risk of NAFL and in one study among a large cohort of 
Italian patients was also associated with severity of liver fibrosis.87,88 
A	polymorphism	 in	 the	 rs641738	variant	of	 the	membrane	bound	
O-acyltransferase domain-containing 7 (MBOAT7) gene, which is 
involved in phosphatidylinositol remodelling, has been associated 
with increased hepatic fat content, more severe hepatocyte injury, 
increased risk of fibrosis and HCC.89,90	Variation	in	17-beta	hydrox-
ysteroid dehydrogenase 13 (HSD17B13) which encodes an enzyme 
localized in lipid droplets within hepatocytes has been associated 
with protection against hepatic inflammation and fibrosis in the set-
ting of metabolic dysfunction.91,92 Similarly, a gene variation at the 
protein	phosphatase	1	regulatory	subunit	3b	(PPP1R3B)	is	thought	
to potentially protect against hepatic fat accumulation and decreases 
risk of progressive liver disease in patients at high risk for NASH.93,94 
Lastly,	 the	 rs12979850	polymorphism	 in	 the	 IFNλ3 gene that par-
ticipates in regulation of innate immunity has been associated with 
increased hepatic inflammation and fibrosis in patients with NAFLD, 
particularly in lean NAFLD.95,96
Several genetic risk scores have been designed to predict the 
presence of NASH, NASH with fibrosis and NAFLD-related HCC. 
These	 are	 reviewed	 in	 detail	 elsewhere	 by	 Vespasiani-Gentilucci	
et al97	A	genetic	risk	score	consisting	of	PNPLA3	rs738409,	TMSF2	
rs58542926	and	Kruppel-like	 factor	6	 (KLF6_rs3750861)	was	able	
to identify individuals at risk for NASH cirrhosis among a larger co-
hort of patients with NAFLD.98 Donati et al reported a significant 
association	between	the	number	of	risk	alleles	(PNPLA3	rs738409,	
TM6SF2	rs58542926	and	MBOAT7	rs641738)	and	the	risk	of	HCC	
(OR 1.6 per allele).89 Lastly, composite biomarker panel was devel-
oped among patients enrolled in the GOLDEN-505 trial of elafibra-
nor to identify patients at risk of fibrosis progression.99 This panel 
included	HgA1c,	miR-34a,	YKL40	 and	 a2m.	The	AUROC	was	0.82	
with	Sn	73%,	Sp	78%,	though	cross	validation	of	this	model	has	not	
been completed as of yet.
5.2 | Proteomics
Proteomics	has	been	applied	to	help	identify	candidate	biomarkers	in	
NASH. A group of three priority 1 proteins (complement component 
C7, insulin-like growth factor acid-labile subunit and transgelin 2) were 
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able to correctly categorize NAFLD patients with NASH with F3/F4 
with	an	AUROC	of	0.91.65
5.3 | Lipidomics and metabolomics
It is hypothesized that lipotoxicity resulting from hepatic inflamma-
tion is a mediator of hepatic fibrosis progression.100 Therefore, inves-
tigators have applied liquid chromatography and mass spectroscopy 
to conduct lipidomic profiling to help identify individuals with NASH 
compared to those with NAFL.101-103 Evaluation of polyunsaturated 
fatty acid metabolites, with a specific focus on arachidonic acid (AA)-
derived eicosanoids, in a nested case-control study (N = 10 NAFL, 
N =	9	NASH,	N	= 10 non-NAFLD) yielded an AUROC of 1.0.101 The 
NASH	ClinLipMet	score	was	derived	using	318	patients	with	liver	bi-
opsies	using	a	combination	of	clinical,	genetic	(PNPLA3	genotype),	li-
pidomic and metabolomics data. This yielded excellent performance 
with	an	AUROC	of	0.86-0.88	to	identify	individuals	with	NASH.104 
Further confirmatory studies evaluating lipidomic and metabolomic 
biomarkers are needed to better establish their role in diagnosis and 
staging of NASH in order to determine their role in clinical practice.
5.4 | Gut microbiome
Differences in gut microbiome have been evoked in the pathogen-
esis and risk of disease progression in NASH. It is hypothesized 
that intestinal microbiota influence hepatic lipid and bile acid 
metabolism and also contribute to endogenous alcohol consump-
tion.105 A small study of patients with NAFLD characterized mi-
crobiota signatures and noted an increase in Bacteroides among 
patients with NASH and an increase in Ruminococcus among pa-
tients with F2-4 compared to those with no to minimal fibrosis.106 
Interestingly, this is in contrast to findings of another study where 
there were lower Ruminococcaceae identified among patients 
with hepatic fibrosis.107 Loomba et al used whole-genome shot-
gun sequencing of stool DNA to detect advanced fibrosis among 
86	patients	with	NAFLD.	Though	not	validated	as	of	yet,	this	clas-
sifier was able to identify patients with F3/4 with an AUROC of 
0.93.108 Shotgun sequencing of faecal metagenomes with mo-
lecular phenomics (hepatic transcriptome and plasma and urine 
metabolites) was conducted among a well-characterized cohort of 
morbidly obese women. This study revealed molecular networks 
linking the gut microbiome and the host phenome to hepatic 
steatosis. Individuals with hepatic steatosis had low microbial 
gene richness and increased genetic potential for processing di-
etary lipids and endotoxin biosynthesis, hepatic inflammation, 
and dysregulation of aromatic and branched-chain amino acid 
metabolism. These molecular phenomic signatures were predic-
tive	of	 hepatic	 steatosis	 (AUROC	0.87).109 Similar findings were 
noted in a twin-family based study that used Magnetic Resonance 
Elastography	(MRE)	with	proton	density	fat	fraction	(PDFF)	to	as-
sess stage of hepatic fibrosis and grade of steatosis.110 Focusing 
on NASH cirrhosis based on MRE, a gut microbiome signature was 
F I G U R E  2  Approach	to	diagnosing	and	staging	NASH:	Clinical	Practice	compared	to	the	research	arena.	Summary	of	categories	of	
methods used for diagnosis and staging of NASH in clinical practice compared to those currently under investigation in the research arena
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identified among a cohort of 203 well-characterized participants 
from a twin and family cohort. A panel of 30 features including 
27 bacterial features was able to detect cirrhosis with an AUROC 
of	0.93.111 Taken together, these data suggest a role for the gut 
microbiome to help distinguish NAFL from NASH and to detect 
advanced fibrosis or cirrhosis in NASH. These results need to be 
further validated in larger, more diverse cohorts, however, before 
they can be applied in clinical practice.
6  | SUMMARY
NAFLD is a significant global public health concern given its high 
prevalence and its associated morbidity and mortality. One of the 
central challenges to managing this burgeoning patient population 
is the difficulty in correctly differentiating individuals with NASH 
from the broader population of patients with NAFL. The other key 
barrier is identification of accurate, noninvasive methods to moni-
tor	response	to	treatment	and	disease	progression.	Presently,	liver	
biopsy remains the gold standard method for diagnosis and staging 
of NASH. Histologic end-points are also commonly used in the re-
search arena for diagnosis and staging, including in NASH clinical 
trials. In clinical practice, liver biopsy is infrequently obtained how-
ever and providers rely on a combination of serum tests, imaging 
and endoscopic data for diagnosis and staging (Figure 2). Numerous 
diagnostic and interventional circulating biomarkers have been in-
vestigated to diagnose and stage NASH as outlined in this review. 
Several clinical decision aides using routinely available laboratory 
and clinical data have been validated to assess for risk of advanced 
fibrosis in NASH and can serve as useful initial risk stratification 
tools.	The	NFS	and	FIB-4	provide	high	NPVs	for	 likelihood	of	ad-
vanced fibrosis, but have limitations in terms of generalizability 
across age groups and categorization of 30% of individuals as hav-
ing indeterminate scores. Serum biomarkers to assess necroinflam-
matory activity in NASH remain more challenging, though a number 
of combination panels have shown promising diagnostic accuracy. 
Emerging data suggest that incorporating novel approaches in-
cluding genomics, proteomics and the gut microbiome may pro-
vide more individualized risk profiles that can better differentiate 
patients at higher risk of disease progression. Genomics data can 
potentially be used to assess risk for fibrosis progression and re-
sponse to therapy and is likely to enter the clinical arena in the fu-
ture.76-78,83	Proteomics	data	have	shown	potential	to	differentiate	
NAFL from NASH, whereas lipidomics, metabolomics and the gut 
microbiome assessments have also been helpful in distinguishing 
stages of fibrosis in NASH.65,102,103,108,109 These ‘omics’ approaches 
require further validation in larger, more heterogeneous cohorts 
before they can be considered for use in clinical practice. Ongoing 
research suggests that combining circulating biomarkers with dy-
namic imaging modalities may yield better performance than using 
either modality alone. This combination approach likely represents 
a mechanism to improve our ability to noninvasively diagnose and 
monitor patients.
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